Adenocarcinoma of the Esophagogastric Junction

di Schneider • 2010 • dettagli prodotto

spedizione gratuita
normalmente disponibile
per la spedizione in 20-25 giorni lavorativi

da €187,19 a € 149,75

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

Aggiungi al carrello
Aggiungi alla lista dei desideri

DESCRIZIONE

Among malignant tumors, adenocarcinomas of the esophagogastric junction show the highest increase in incidence over the past three decades in Western industrialized countries. Accordingly, much effort is being devoted to basic and translational research in order to combat this frequently deadly disease. This special volume, with contributions from experts in the field, covers all aspects of adenocarcinomas of the esophagogastric junction. Etiology, pathogenesis, classification, and clinical staging are discussed, and there is special emphasis on state of the art treatment techniques. The latter range from endoscopic mucosal resections or limited surgical resections for early cancers to multimodality treatment options for locally advanced tumors. Emerging quality issues in surgical management are also addressed. Detailed attention is paid to other important recent developments, including molecular response prediction in multimodality treatment and early metabolic response evaluation by PET and PET-CT during neoadjuvant treatment. The diagnosis of micrometastases and its potential impact on therapeutic strategies are explored, and the use of sentinel node technology is assessed. This volume will be of interest to all clinicians concerned with the diagnosis and management of this malignancy.Table of contents Epidemiology of adenocarcinoma of the esophagogastric junction (EJ).- Clinical classification systems.- Histopathologic classification.- The pathogenesis of Barrett’s metaplasia and the progression to esophageal adenocarcinoma.- Differences in the molecular biology of adenocarcinoma of the EJ.- Clinical staging.- Endoscopic mucosal resection for staging and therapy.- Surgical strategies.- Current status of sentinal lymph node biopsy in adenocarcinoma of the EJ.- Current diagnosis and future impact of micrometastases for therapeutic strategies.- Quality indicators in the surgical management of adenocarcinoma of the EJ.- Perioperative and complication management.- Multimodality therapy.- Metabolic response evaluation by PET during neoadjuvant treatment.- Molecular response prediction in multimodality treatment.